Abstract 2763
Background
Tobacco smoking is the major risk factor for lung cancer. However, approximately 10% of patients diagnosed with lung cancer have never smoked and knowledge of their characteristics and survival remain limited. Specific genetic alterations, e.g. ALK (anaplastic lymphoma kinase) rearrangements and EGFR (epidermal growth factor receptor) mutations, are more common in never-smoking lung cancer patients than in current or former smokers. We aimed to investigate characteristics of patients with different smoking history and estimate their lung cancer-specific survival.
Methods
This study was based on data from the Lung Cancer Database Sweden generated by record linkage between the Swedish National Lung Cancer Register and other population-based registers. Patients diagnosed with primary non-small cell lung cancer between 2002 and 2016 were included. The Kaplan-Meier method was used to estimate lung cancer-specific survival by smoking history (never-smokers, former smokers, and current smokers).
Results
In total, 41,262 patients with lung cancer were included, of those 4,624 (11.2%) had never smoked. Never-smokers were older at time of the diagnosis (median: 73 years, Inter Quartile Range (IQR)=63-80) than current smokers (median: 67 years, IQR=61-73) and former smokers (median: 72 years, IQR=66-78). Women were overrepresented among never-smokers (66%) than among current (49%) and former smokers (43%). Adenocarcinoma was the most frequent histological subtype in all groups, but was proportionally more frequent in never-smokers (77%) compared to current smokers (52%) and former smokers (57%). The estimated overall (all stages) 2-year cause specific lung cancer survival was higher in never-smokers (35.9%, 95% CI 34.4 - 37.5) than among current smokers (29.4%, 95% CI 28.7 - 30.2) and former smokers (30.7%, 95% CI 30.0 -31.4).
Conclusions
The observed longer survival and the difference in histopathology suggest that tumours in never-smokers have a different pathogenesis and a different behaviour than tobacco-associated lung cancer. In further analyses, we will examine observed differences in outcomes in more detail, including the modifying role of other prognostic factors.
Clinical trial identification
Legal entity responsible for the study
Regional Oncologic Centre Uppsala-Örebro and Karolinska Institutet.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract